Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Resistance to key malaria drug spreading at alarming rate in Southeast Asia

31.07.2014

Longer treatment courses with combination therapies prove effective in areas with drug resistance

WHAT:

Resistance to artemisinin, the main drug to treat malaria, is now widespread throughout Southeast Asia, among the Plasmodium falciparum (P. falciparum) parasites that cause the disease and is likely caused by a genetic mutation in the parasites.

However, a six-day course of artemisinin-based combination therapy—as opposed to a standard three-day course—has proved highly effective in treating drug-resistant malaria cases, according to findings published today in the New England Journal of Medicine. The research was conducted by an international team of scientists including those from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Previous clinical and laboratory studies suggest that P. falciparum parasites with a mutant version of a gene called K13-propeller are resistant to artemisinin. In the new study, researchers found that the geographic distribution of these mutant parasites in Western Cambodia corresponded with the recent spread of drug resistance among malaria patients in that region.

Although artemisinin continued to effectively clear malaria infections among patients in this region, the parasites with the genetic mutation were eliminated more slowly, according to the authors. Slow-clearing infections strongly associated with this genetic mutation were found in additional areas, validating this marker of resistance outside of Cambodia. Artemisinin resistance is now firmly established in areas of Cambodia, Myanmar, Thailand and Vietnam, according to the authors.

As a potential treatment, the researchers tested a six-day course of artemisinin-based combination therapy in Western Cambodia and found the regimen to be effective in this region, where resistance has become the most problematic. To contain the further spread of artemisinin resistance, continued geographical monitoring is needed as well as a re-examination of standard malaria treatment regimens and the development of new therapy options, the authors write.

###

ARTICLE:

EA Ashley et al. The spread of artemisinin resistance in falciparum malaria. New England Journal of Medicine DOI: 10.1056/NEJMoa1314981.

WHO:

NIAID Director Anthony S. Fauci, M.D., is available to comment on this research. Rick M. Fairhurst, M.D., Ph.D., chief of the Malaria Pathogenesis and Human Immunity Unit in NIAID's Laboratory of Malaria and Vector Research, is a co-author on the paper and is also available for comment.

CONTACT:

To schedule interviews, please contact Jennifer Routh, (301) 402-1663, jennifer.routh@nih.gov.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

About the National Institutes of Health (NIH):

NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

Jennifer Routh | Eurek Alert!

Further reports about: Allergy Human Infectious Medicine NIAID NIH falciparum infections malaria parasites

More articles from Health and Medicine:

nachricht Mobile phone test can reveal vision problems in time
11.02.2016 | University of Gothenburg

nachricht Proteomics and precision medicine
08.02.2016 | University of Iowa Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Production of an AIDS vaccine in algae

Today, plants and microorganisms are heavily used for the production of medicinal products. The production of biopharmaceuticals in plants, also referred to as “Molecular Pharming”, represents a continuously growing field of plant biotechnology. Preferred host organisms include yeast and crop plants, such as maize and potato – plants with high demands. With the help of a special algal strain, the research team of Prof. Ralph Bock at the Max Planck Institute of Molecular Plant Physiology in Potsdam strives to develop a more efficient and resource-saving system for the production of medicines and vaccines. They tested its practicality by synthesizing a component of a potential AIDS vaccine.

The use of plants and microorganisms to produce pharmaceuticals is nothing new. In 1982, bacteria were genetically modified to produce human insulin, a drug...

Im Focus: The most accurate optical single-ion clock worldwide

Atomic clock experts from the Physikalisch-Technische Bundesanstalt (PTB) are the first research group in the world to have built an optical single-ion clock which attains an accuracy which had only been predicted theoretically so far. Their optical ytterbium clock achieved a relative systematic measurement uncertainty of 3 E-18. The results have been published in the current issue of the scientific journal "Physical Review Letters".

Atomic clock experts from the Physikalisch-Technische Bundesanstalt (PTB) are the first research group in the world to have built an optical single-ion clock...

Im Focus: Goodbye ground control: autonomous nanosatellites

The University of Würzburg has two new space projects in the pipeline which are concerned with the observation of planets and autonomous fault correction aboard satellites. The German Federal Ministry of Economic Affairs and Energy funds the projects with around 1.6 million euros.

Detecting tornadoes that sweep across Mars. Discovering meteors that fall to Earth. Investigating strange lightning that flashes from Earth's atmosphere into...

Im Focus: Flow phenomena on solid surfaces: Physicists highlight key role played by boundary layer velocity

Physicists from Saarland University and the ESPCI in Paris have shown how liquids on solid surfaces can be made to slide over the surface a bit like a bobsleigh on ice. The key is to apply a coating at the boundary between the liquid and the surface that induces the liquid to slip. This results in an increase in the average flow velocity of the liquid and its throughput. This was demonstrated by studying the behaviour of droplets on surfaces with different coatings as they evolved into the equilibrium state. The results could prove useful in optimizing industrial processes, such as the extrusion of plastics.

The study has been published in the respected academic journal PNAS (Proceedings of the National Academy of Sciences of the United States of America).

Im Focus: New study: How stable is the West Antarctic Ice Sheet?

Exceeding critical temperature limits in the Southern Ocean may cause the collapse of ice sheets and a sharp rise in sea levels

A future warming of the Southern Ocean caused by rising greenhouse gas concentrations in the atmosphere may severely disrupt the stability of the West...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Symposium on Climate Change Adaptation in Africa 2016

12.02.2016 | Event News

Travel grants available: Meet the world’s most proficient mathematicians and computer scientists

09.02.2016 | Event News

AKL’16: Experience Laser Technology Live in Europe´s Largest Laser Application Center!

02.02.2016 | Event News

 
Latest News

LIGO confirms RIT's breakthrough prediction of gravitational waves

12.02.2016 | Physics and Astronomy

Gene switch may repair DNA and prevent cancer

12.02.2016 | Life Sciences

Using 'Pacemakers' in spinal cord injuries

12.02.2016 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>